Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisJeffrey A. Cohen, Ludwig Kappos, Frederik Barkhof et al.|New England Journal of Medicine|2010Cited by 2.2k
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS studyBhupendra Khatri, Jeffrey A. Cohen, Frederik Barkhof et al.|The Lancet Neurology|2011Cited by 216
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJeffrey A. Cohen, Ludwig Kappos, Bhupendra Khatri et al.|Journal of Neurology Neurosurgery & Psychiatry|2015Cited by 163
The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130